Currently, over 100,000 individuals in the US are on the waiting list for organ transplants. Kidney patients make up the majority of the requests, with over 90,000 people hoping for donor organs. Data shows that seventeen people die every day while they are waiting for new organs; meanwhile, one new patient is added to the list every ten minutes.
Modern options, such as bioprinting may one day eliminate the need for treatments like dialysis, and companies like Organovo have previously served as pioneers in the field of 3D printed kidneys. Now, Israel’s CollPlant Biotechnologies and United Therapeutics are amping up their collaboration further to bioprint kidneys, with the ultimate goal of transplantation.
“Organ shortages are an unmet global health need and by partnering with United Therapeutics for the past couple of years, we have made significant progress with this pivotal organ manufacturing initiative,” explained Yehiel Tal, CollPlant CEO.
CollPlant is entirely dedicated to “regenerative and aesthetic medicine” in relation to tissue regeneration and the creation of human organs. For bioprinting, the CollPlant team relies on their rhCollagen-based bioinks. United Therapeutics, in complement to the technology of CollPlant, is focused on developing products to improve treatment for patients suffering from chronic and life-threatening health issues.
The two companies have been working together since 2018, with great enthusiasm shared for the CollPlant technology, using tobacco plants to make collagen-expressing plants that could lead to the production of a variety of human organs.
“Our collagen-expressing plants are already flourishing in Texas where we enjoy three growing seasons,” says Martine Rothblatt, PhD, chairman and CEO of United Therapeutics.
The two companies originally began working together to use 3D printing in lung transplants. Continuing on, the extension of their collaboration includes a $3 million payment to CollPlant for licensing of their collagen and bioink products. The original agreement included $5 million, with “milestone payments of up to $15 million,” depending on development details.
[Source / Images: Genetic Engineering & BioTechnology News]
“United Therapeutics is pioneering the emerging organ manufacturing field, and we are honored to be part of this effort via this partnership. This option exercise demonstrates another important validation of our rhCollagen platform technology, performing as an optimal building block for regenerative medicine. We remain committed to exploring new innovative applications in the fields of medical aesthetics and 3D bioprinting of tissues and organs,” said Tal.
Subscribe to Our Email Newsletter
Stay up-to-date on all the latest news from the 3D printing industry and receive information and offers from third party vendors.
You May Also Like
Wimba Aims to Mainstream 3D Printed Animal Prosthetics
While additive manufacturing (AM) has been used to produce prosthetics for humans and animals, there have yet to be many dedicated businesses for applying the technology strictly to making them...
A First-Timer’s “Definitive” Guide to Surviving Formnext
Believe it or not, this year was my very first time attending the additive manufacturing (AM) industry powerhouse event known as formnext, which has been held in Germany for eight...
Desktop Metal: AM 2.0 Highlights from the Formnext Show Floor
Formnext, the leading international platform for Additive Manufacturing and industrial 3D Printing, returned in full swing to the halls of the Frankfurt convention center in Germany this November. With challenging...
3D Printing News Briefs, November 26, 2022: 3D Printed Coral Reefs & Moon Habitat & More
In today’s 3D Printing News Briefs, Carbon’s bioabsorbable elastomer platform is biocompatible in vivo, while researchers in Germany and Australia developed a 3D printing resin and dedicated printer that enable...